Liu K, Choi J, Le A, et al. - In this investigation, researchers assessed the effect of long-term tenofovir disoproxil fumarate (TDF) treatment on the risk of hepatocellular carcinoma (HCC), hepatic decompensation and death by comparing a large multi-national real-life cohort of treated chronic hepatitis B (CHB), a serious public health problem with an estimated 248 million carriers of the virus globally, patients with cirrhosis and a historical cohort of untreated CHB patients with cirrhosis. The study sample consisted of 1,088 (291 untreated and 797 TDF-treated) patients. According to findings, TDF treatment in CHB patients with cirrhosis at 5 years decreases the risks of HCC, hepatic decompensation, liver-related mortality and all-cause mortality. These risk declines are also reflected in continued improvements in validated prognostic scores for anticipating HCC and liver events indicating that TDF treatment changes these patients' natural history of the disease.